ETV1
ETV1 (ETS translocation variant 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Pancreatic ductal adenocarcinoma, Breast cancer and 4 more.
Overview
Transcriptional activator that binds to DNA sequences containing the consensus pentanucleotide 5'-CGGA[AT]-3'. Required for olfactory dopaminergic neuron differentiation; may directly activate expression of tyrosine hydroxylase (TH).
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Trametinib. Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes genetic literature 0.61, literature 0.97, genetic association 0.42, somatic mutation 0.83, animal model 0.39). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Invasive Breast Carcinoma, Colon Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ETV1 (ETS translocation variant 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Pancreatic ductal adenocarcinoma, Breast cancer and 4 more.
- 1 · What it is
ETV1 (ETS translocation variant 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Pancreatic ductal adenocarcinoma, Breast cancer and 4 more.
- 2 · What goes wrong in cancer
Transcriptional activator that binds to DNA sequences containing the consensus pentanucleotide 5'-CGGA[AT]-3'. Required for olfactory dopaminergic neuron differentiation; may directly activate expression of tyrosine hydroxylase (TH).
- 3 · How drugs use it
No product in this corpus aims at ETV1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:3490 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P50549 (protein name, function text, keywords and locations (REST API)); CIViC gene ETV1 (2 evidence items, 0 assertions, 1 variants; diseases: Lung Cancer, Pancreatic Cancer (GraphQL API, CC0)); Open Targets ENSG00000006468 (association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: gastric cancer 0.52, prostate cancer 0.57, sarcoma 0.50, lung cancer 0.53 (GraphQL API, CC0)); IntOGen ETV1 (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional activator that binds to DNA sequences containing the consensus pentanucleotide 5'-CGGA[AT]-3'. Required for olfactory dopaminergic neuron differentiation; may directly activate expression of tyrosine hydroxylase (TH). Location: Nucleus (UniProt). Locus 7p21.2 (HGNC).
- Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903); CIViC evidence names this disease
- Pancreatic ductal adenocarcinoma: CIViC evidence names this disease
- Breast cancer: IntOGen driver in 1 cohort (BRCA)
- Colorectal cancer: IntOGen driver in 1 cohort (COAD)
- Prostate cancer: Open Targets association 0.57 with prostate cancer (MONDO_0008315)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.52 with gastric cancer (MONDO_0001056)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 2 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ETV1" OR ABSTRACT:"ETV1" OR TITLE:"ETS variant transcription factor 1" OR ABSTRACT:"ETS variant transcription factor 1" OR TITLE:"ETS translocation variant 1" OR ABSTRACT:"ETS translocation variant 1" OR TITLE:"ER81" OR ABSTRACT:"ER81") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ETV1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPALB2
Shares Lung cancer (all types), Breast cancer (all types), CIViC, IntOGen.
- TargetCHEK2
Shares Lung cancer (all types), Sarcomas (soft tissue, bone, GIST), Breast cancer (all types), CIViC.
- TargetBARD1
Shares Lung cancer (all types), Breast cancer (all types), CIViC, IntOGen.
- TargetKDM6A
Shares Lung cancer (all types), Breast cancer (all types), CIViC, IntOGen.
- TargetLRP1B
Shares Lung cancer (all types), Breast cancer (all types), CIViC, IntOGen.
- TargetKMT2C
Shares Lung cancer (all types), Breast cancer (all types), CIViC, IntOGen.
- TargetFGFR4
Shares Lung cancer (all types), Sarcomas (soft tissue, bone, GIST), Breast cancer (all types), CIViC.
- TargetCACNA1D
Shares Lung cancer (all types), Sarcomas (soft tissue, bone, GIST), Breast cancer (all types), IntOGen.